What are the most common MK-677 side effects?

In the Nass et al. two-year trial at 25 mg daily, the most common were increased appetite (67% vs 36% placebo), transient mild lower-limb edema (44% vs 27%) and transient muscle pain (33% vs 9%). The appetite effect returned to normal within about three months in roughly half of subjects. These are published clinical-trial figures reproduced as a research reference, not medical advice.

Does MK-677 raise blood sugar?

The Nass trial found fasting glucose rose by an average of about 0.3 mmol/L (5 mg/dL) with a decrease in insulin sensitivity, and other sources report HbA1c increases with longer use. Because the ghrelin receptor acts directly on pancreatic beta cells, the metabolic effect is not only a downstream IGF-1 consequence. This is the most-cited reason MK-677 is approached cautiously in anyone with glucose concerns.

How is MK-677 different from an injectable like ipamorelin?

MK-677 is an oral non-peptide ghrelin mimetic, so its profile is dominated by appetite and a glucose/insulin shift. Ipamorelin — part of the injectable CJC-1295/ipamorelin blend Titan stocks — is a selective GHRP that does not trigger the same hunger spike and has a different metabolic footprint. Reading MK-677's appetite-and-glucose-heavy record is the clearest way to see why the selective injectable is a different trade-off.

Is MK-677 approved for human use?

No. MK-677 (ibutamoren) is not FDA-approved for any indication and never completed development. Titan does not supply it. Titan Peptide Lab supplies the CJC-1295/ipamorelin blend strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The adverse-event data here summarises published clinical research and is not medical or dosing advice.

MK-677 · adverse-event profile · research use only

MK-677 side effects, as the two-year trial actually recorded them.

Unlike most compounds in this category, MK-677 (ibutamoren) has real long-term human data: the Nass et al. two-year, double-blind trial published in the Annals of Internal Medicine in 2008, in 65 healthy older adults on 25 mg daily. That trial is the reason its adverse-event profile can be quoted rather than guessed. Two features define it. First, because MK-677 is an oral ghrelin-receptor mimetic, its effects cluster around appetite and fluid — increased hunger, transient lower-limb edema, muscle pain. Second, and more important for anyone reading it critically, it nudges fasting glucose up and insulin sensitivity down, and an earlier clinical program was halted over a congestive-heart-failure concern. This page reproduces that record as a research reference. One honesty note: MK-677 is an oral non-peptide, not an injectable peptide, and Titan does not stock it — the compound it points to is the injectable CJC-1295/ipamorelin blend, a different route to the same GH axis. It is a summary of published trial data, not a human-use protocol or medical advice.

CJC-1295 + Ipamorelin blend — $119.99 MK-677 vs Ipamorelin

Appetite is the signature effect

MK-677 mimics ghrelin, the hunger hormone, so increased appetite is the most consistent finding. In the Nass trial it was reported in 67% of the MK-677 group versus 36% on placebo — but with a useful detail: in about half of those, appetite returned to normal within three months, and more gradually in the rest. So it is a common effect that tends to attenuate, not a permanent one. It is also the mechanism most responsible for the weight gain seen on the compound.

MK-677 dosage reference →

Fluid retention and muscle pain

The next most common effects in the two-year data were transient, mild lower-extremity edema (44% vs 27% placebo) and transient muscle pain (33% vs 9%). Both are consistent with GH-axis stimulation and both were described as transient. The trial's authors specifically contrasted this with injected growth hormone, which produces more pronounced edema, arthralgia and carpal-tunnel effects — the point being that physiologically stimulated GH tends to be milder than exogenous GH, not that it is free of fluid effects.

How it compares to a GHRP →

The glucose signal is the one to read carefully

This is the effect that matters most for interpreting MK-677. In the Nass trial fasting blood glucose rose by an average of 0.3 mmol/L (about 5 mg/dL, p=0.015) and insulin sensitivity decreased. The ghrelin receptor has direct effects on pancreatic beta-cell function, so the metabolic shift is not purely a downstream IGF-1 effect. Other sources note increases in HbA1c with longer use. It is the single most-cited reason MK-677 is treated cautiously in anyone with glucose concerns.

Research-use policy →

The heart-failure signal

An earlier MK-677 clinical program in a frail, older, hospitalised population was reportedly stopped over a concern that the drug increased the risk of congestive heart failure. This is frequently cited by anti-doping and public-health bodies. The Nass trial in healthy older adults did not report that outcome, so the signal is population- and context-dependent rather than a universal finding — but it is a documented reason the compound never reached approval and is worth reading alongside the fluid-retention effect.

Timeline of the GH axis →

What it does NOT do — and the identity question

On the reassuring side: Copinschi (1996) found no change in 24-hour mean cortisol at therapeutic doses, and prolactin rose only modestly (~23%, within normal range). LDL cholesterol fell slightly in the Nass trial. But there is a verification twist unique to MK-677: it is a small-molecule non-peptide (ibutamoren mesylate), so its identity is confirmed by small-molecule HPLC/MS against a reference standard and its salt form — not by a peptide sequence. A 'sequence + 99% pure' certificate is the wrong test for this compound entirely.

How identity is verified →

Why this page points to the injectable blend

Titan does not stock MK-677. It reaches the GH axis a different way — the injectable CJC-1295/ipamorelin blend, where ipamorelin's receptor selectivity avoids the appetite spike (it does not trigger the GHRP-6-style hunger) and the glucose picture differs from an oral ghrelin mimetic. Reading MK-677's appetite-and-glucose-dominated profile is the cleanest way to understand why a selective injectable is a different trade-off. This page does not imply Titan sells MK-677.

CJC-1295 + Ipamorelin — $119.99 →

The detail, in plain terms

The adverse-event table, at a glance.

Figures below are drawn primarily from the Nass et al. 2008 two-year trial (25 mg/day, 65 healthy older adults), with supporting notes from earlier studies, reproduced as a research reference. Exact figures vary by study and population. Titan does not stock MK-677.

Increased appetite: 67% vs 36% placebo (Nass 2008); normalised within ~3 months in ~half of subjects.
Lower-limb edema: 44% vs 27% placebo; mild and transient.
Muscle pain: 33% vs 9% placebo; transient.
Fasting glucose: Rose ~0.3 mmol/L (~5 mg/dL, p=0.015); insulin sensitivity decreased; HbA1c rises reported with longer use.
Body weight: Increased ~2.7 kg over the trial vs ~0.8 kg placebo.
Cortisol / prolactin: No change in 24-h mean cortisol (Copinschi 1996); prolactin +~23%, within normal range.
Heart-failure signal: An earlier trial in frail hospitalised patients was reportedly halted over a CHF concern — context-dependent, not seen in healthy-adult data.
Identity check: Small-molecule (ibutamoren mesylate): HPLC/MS + salt-form verification, NOT a peptide sequence or bare purity %.

Questions researchers ask

Before you order.

What are the most common MK-677 side effects?: In the Nass et al. two-year trial at 25 mg daily, the most common were increased appetite (67% vs 36% placebo), transient mild lower-limb edema (44% vs 27%) and transient muscle pain (33% vs 9%). The appetite effect returned to normal within about three months in roughly half of subjects. These are published clinical-trial figures reproduced as a research reference, not medical advice.
Does MK-677 raise blood sugar?: The Nass trial found fasting glucose rose by an average of about 0.3 mmol/L (5 mg/dL) with a decrease in insulin sensitivity, and other sources report HbA1c increases with longer use. Because the ghrelin receptor acts directly on pancreatic beta cells, the metabolic effect is not only a downstream IGF-1 consequence. This is the most-cited reason MK-677 is approached cautiously in anyone with glucose concerns.
Is the MK-677 heart-failure concern real?: An earlier MK-677 clinical program in a frail, older, hospitalised population was reportedly stopped over a congestive-heart-failure concern, which anti-doping and public-health bodies cite. The two-year Nass trial in healthy older adults did not report that outcome, so the signal appears population- and context-dependent rather than universal — but it is a documented reason the compound never reached approval and should be read alongside its fluid-retention effect.
How is MK-677 different from an injectable like ipamorelin?: MK-677 is an oral non-peptide ghrelin mimetic, so its profile is dominated by appetite and a glucose/insulin shift. Ipamorelin — part of the injectable CJC-1295/ipamorelin blend Titan stocks — is a selective GHRP that does not trigger the same hunger spike and has a different metabolic footprint. Reading MK-677's appetite-and-glucose-heavy record is the clearest way to see why the selective injectable is a different trade-off.
Is MK-677 approved for human use?: No. MK-677 (ibutamoren) is not FDA-approved for any indication and never completed development. Titan does not supply it. Titan Peptide Lab supplies the CJC-1295/ipamorelin blend strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption. The adverse-event data here summarises published clinical research and is not medical or dosing advice.